Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $4.13 Analyst target: $13.00 Upside: 214.77%
Taysha Gene Therapies, Inc., a gene therapy company, focuses on the development and commercialization of adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. The company is headquartered in Dallas, Texas.
See the full interactive analysis & chart →Informational only — not investment advice.